Ioannidis John P A, Contopoulos-Ioannidis Despina G, Rosenberg Philip S, Goedert James J, De Rossi Anita, Espanol Teresa, Frenkel Lisa, Mayaux Marie-Jeanne, Newell Marie-Louise, Pahwa Savita G, Rousseau Christine, Scarlatti Gabriella, Sei Shizuko, Sen Luisa, O'Brien Thomas R
Clinical and Molecular Epidemiology Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
AIDS. 2003 Jul 25;17(11):1631-8. doi: 10.1097/01.aids.0000060411.18106.0f.
Among perinatally infected children, the effects of certain alleles of the CCR5 and CCR2 genes on the rate of disease progression remain unclear. We addressed the effects of CCR5-delta32 and CCR2-64I in an international meta-analysis.
Genotype data were contributed from 10 studies with 1317 HIV-1-infected children (7263 person-years of follow-up). Time-to-event analyses were performed stratified by study and racial group. Endpoints included progression to clinical AIDS, death, and death after the diagnosis of clinical AIDS. The time-dependence of the genetic effects was specifically investigated.
There was large heterogeneity in the observed rates of disease progression between different cohorts. For progression to clinical AIDS, both CCR5-delta32 and CCR2-64I showed overall non-significant trends for protection [hazard ratios 0.84, 95% confidence interval (CI) 0.58-1.23; and 0.87, 95% CI 0.67-1.14, respectively]. However, analyses of survival showed statistically significant time-dependence. No deaths occurred among CCR5-delta32 carriers in the first 3 years of life, whereas there was no protective effect (hazard ratio 0.95; 95% CI 0.43-2.10) in later years (P=0.01 for the time-dependent model). For CCR2-64I, the hazard ratio for death was 0.69 (95% CI 0.39-1.21) in the first 6 years of life and 2.56 (95% CI 1.26-5.20) in subsequent years (P<0.01 for the time-dependent model). CCR5-delta32 and CCR2-64I offered no clear protection after clinical AIDS had developed.
The CCR5-delta32 and CCR2-64I alleles are associated with a decreased risk of death among perinatally infected children, but only for the first years of life.
在围产期感染儿童中,CCR5和CCR2基因的某些等位基因对疾病进展速度的影响尚不清楚。我们通过一项国际荟萃分析研究了CCR5-Δ32和CCR2-64I的影响。
基因型数据来自10项研究,共1317名感染HIV-1的儿童(随访7263人年)。按研究和种族分组进行事件发生时间分析。终点包括进展至临床艾滋病、死亡以及临床艾滋病诊断后的死亡。特别研究了基因效应的时间依赖性。
不同队列中观察到的疾病进展率存在很大异质性。对于进展至临床艾滋病,CCR5-Δ32和CCR2-64I总体上均显示出不显著的保护趋势[风险比分别为0.84,95%置信区间(CI)0.58 - 1.23;以及0.87,95%CI 0.67 - 1.14]。然而,生存分析显示出统计学上显著的时间依赖性。CCR5-Δ32携带者在生命的前3年没有死亡,而在随后几年没有保护作用(风险比0.95;95%CI 0.43 - 2.10)(时间依赖性模型P = 0.01)。对于CCR2-64I,生命前6年的死亡风险比为0.69(95%CI 0.39 - 1.21),随后几年为2.56(95%CI 1.26 - 5.20)(时间依赖性模型P<0.01)。临床艾滋病发生后,CCR5-Δ32和CCR2-64I没有提供明确的保护作用。
CCR5-Δ32和CCR2-64I等位基因与围产期感染儿童死亡风险降低有关,但仅在生命的最初几年。